3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Suspended
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
12
Leukemia, Myeloid, Acute
12
Neoplasm Metastasis
9
Melanoma
7
Breast Neoplasms
7
Prostatic Neoplasms
6
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Colorectal Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Myelodysplastic Syndromes
5
Lung Neoplasms
5
Glioma
5
Hematologic Neoplasms
4
Glioblastoma
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Solid Tumors
3
Small Cell Lung Carcinoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma
3
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Solid Tumor
2
Sarcoma
2
Osteosarcoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, B-Cell
2
Interventions
talazoparib
1
CX 5461
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Suspended
×
Metastatic Castration Resistant Prostate Cancer (mCRPC)
×
Clear all
NCT05425862
2023-12-11
REPAIR
Peter MacCallum Cancer Centre, Australia
Phase 1
Suspended
48 enrolled